QIBA 2018 CT Volumetry Biomarker Committee: Overview and Status Update


Marthony Robins, PhD; Jenifer Siegelman, MD, MPH; Jayashree Kalpathy-Cramer, PhD; Rudresh Jarecha, MBBS, DNB, DMRE; Maria Athelogou, PhD; Andrew Buckler, MS; Kevin O'Donnell, MASc; Nancy Obuchowski, PhD; Nicholas Petrick, PhD; Berkman Sahiner, PhD; Ehsan Samei, PhD

Volumetry in Dynamic Contrast-Enhanced Liver CT


Clinically accurate and precise liver lesion sizing depends on local anatomical complexity, underlying disease, patient physiology, contrast injection, and CT technical acquisition

Aims: To create a phantom emulating clinical conditions for evaluating sizing of low contrast hepatic lesions and to use it to investigate hepatic lesion sizing error as a function of:


- Acquisition Reconstruction Lesion Size/Shape/Contrast
- Study 1: impact of acquisition and lesion characteristics




scanners, 3 doses, 4 slice hickness: 38 lesions: Lesion olume estimated with a egmentation and a low-bias 3D mplate matching algorithm Conclusion: Poor measurability or lesions ≤10mm. Good epeatability for slice nicknesses between 1.5-5 mm d lesions >10 mm




Study 2: impact of recon algorithm





Hybrid Data for CT Volumetry Advanced Disease Profile is now in Thoracic CT Testing **Technically Confirmed** Creation of a set of blended CT scans that "look and feel" like actual clinical scans of patients with tumors. Will allow testing of algorithms for measurement of tumors What if ground truth is know with known volumes. **Next step: Claim Confirmed** Test the precision and virtually insert lung and liver lesions of known shape, accuracy volume, and texture into clinical CT images your algorithm to quantify lesion In 2018, the CTVAD Profile reached the Technically Confirmed Stage, which volume means that field testing confirmed the requirements and procedures in the Profile Lesion are practical and feasible when executed in a normal imaging environment. Field blending i testing feedback resulted in a number of revisions and simplifications. image domain The field testing was performed at: Duke University School of Medicine National Institute of Biomedical Imaging and Bioengineering Rush University Medical Center 2. Develop datasets of clinical CT scans with virtually inserted lesions and disseminate lesion insertion software Columbia University Medical Center Lung Datasets The Technically Confirmed version of the CTVAD Profile is published at: http://gibawiki.rsna.org/index.php/Profiles The next stage is Claim Confirmed, which involves field testing the profile again with a focus on confirming it is possible to achieve the performance stated in the Claim by conforming to the Profile requirements and procedures. inserted nodules clinical images containing real lung lesions and virtually Please see below for opportunities to get involved in the effort inserted lesion models **Liver Datasets Doctor / Technologist / Physicist:** Method A is a projection-domain insertion technique Participate in clinical testing of the Advanced Disease Profile and get the inside track on QIBA Method B and C are image-domain insertion techniques compliant protocols Startup / Vendor / Researcher: time needed 8-40 hrs Evaluate applicability of the profile to your commercial / research activities % Bias ± 95% CI Government / CRO / Pharma: time needed 6-8 hrs Evaluate QIBA Profile requirements and performance claims in your clinical trial design 3. Disseminate lesion insertion software Provision is made to provide All Interested: % a resource to generate Join QIBA, Meet Virtually, Create Consensus Profiles dynamic datasets based on a priori statistical definitions for Attend Live Sessions at RSNA Gaussian Blur Setting the formation of variable "Advances in CT: Technologies, Applications, Operations – Quantitative CT (QIBA)" (**RC121**): datasets using the Duke Method 3 a) 🔳 (major) 📓 Lessor Physical Method 2 Sunday, 11/25 – 2:00-3:30pm, Room E351 Lesion Tool. These reference Insertion Type datasets are designed to be 2. "Quantitative Imaging Applications in Screening, Treatment Selection, and Treatment used to conduct evaluation of All Algorithms Compliant Algorithms Assessment – the Need for Standardization in the Era of Personalized Medicine" (SPSI21): quantitative performance DECIMa in Lind Inages DF C7 Dels in Pagert -Monday, 11/26 – 4:30-6:00pm, Room S504AB across commercial and research software packages We acknowledge the contributions of committee participants and RSNA Staff: for lesion volumetry, texture and morphology analysis. Joseph Koudelik, Julie Lisiecki, Fiona Miller is not equivalent, but they correlate, such that, volumetrically The database will be made simulated lesions could potentially serve as practical proxies publically available so For supplemental materials, and to add your name for consideration as a test site, institutions can benchmark find us at: http://gibawiki.rsna.org/index.php/Invitation to Participate Duke Lesion Tool: used for modeling lesions and their volumetry, texture and morphology software using a a dynamic hybrid dataset. Various QIBA projects and activities have been funded in whole or in part with Federal funds from the National Institute of validated reference clinical Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Service, under dataset without the need for Contracts Nos. HHSN268201000050C, HHSN268201300071C, and HHSN268201500021C. additional image acquisition.

Volumetry of Pulmonary Lesions CT Virtual Clinical Trial Grand Challenge Aims: To quantitatively benchmark volume estimation performance of image analysis tools To provide a quantitative understanding of differences between approaches Methods: Image-based segmentation on datasets generated using 1. an anthropomorphic phantom with synthetic and virtually Nodules virtually inserted using three methods: **Results:** Data from 21 national and international participants were analyzed for bias and precision of estimated volumes Conclusions: 1. four of 21 participants meet QIBA compliance criteria 2. technical performance between physical and virtual insertion Robins, M., Kalpathy-Cramer, J., Obuchowski, N. A., Buckler, A., Athelogou, M., Jarecha, R., et al. "Evaluation of Simulated Lesions as Surrogates to Clinical Lesions for Thoracic CT Volumetry: The Results of an International Challenge". Academic radiology. (2018).




3.87mGy


19.0mGy

7.6mGy




Use projection and image-domain lesion insertion tools to










providing a platform for lesion insertion for creating

CT Quantification Beyond Volume: Texture, Morphology


Creation of a library of anthropomorphic lesion simulations with a priori internal texture, morphology, and volumes.

. Simulate heterogeneous structures (texture) within lesions




3D modeled lesion rendition > Crosssectional view of a realistic textured lesion

2. Assess imaging system impact on lesion texture



3. Develop a framework to analyze scanner and protocolspecific texture influence



Reconstruction kernel-based % difference between the ground truth texture features (i.e., pre-imaged) and the imaged texture feature measurements

4. Assessing variation across imaging system & morphology

Slice Thickness (mm)

